STARPHARMA HOLDINGS

SPL
Delayed Quote. Delayed  - 01/21 12:10:21 am
1.11AUD -3.06%

Starpharma Announces It Has Signed an Initial Supply Contract for VIRALEZE Antiviral Nasal Spray in Vietnam and First Delivery into Vietnam Is Expected in Early November

10/25/2021 | 06:57pm
Starpharma announced it has signed an initial supply contract for VIRALEZETM antiviral nasal spray in Vietnam and first delivery into Vietnam is expected in early November. In parallel with completing registration, Starpharma is finalizing an ongoing distribution agreement for VIRALEZETM in Vietnam which will allow subsequent larger orders and ongoing supply. Vietnam, which has a population of approximately 97 million, is experiencing a significant Delta outbreak with ~20% of its population fully vaccinated1. According to figures from the World Health Organization, the death toll in Vietnam from COVID-19 exceeds 21,000 2. Starpharma's initial orders committed for purchase under this initial supply distribution contract for VIRALEZETM to Vietnam total approximately 100,000 units of VIRALEZETM with further larger orders expected upon signing of an ongoing distribution agreement, which is currently being finalized. The distribution arrangements for Vietnam include Australian-based Healthco Australia Pty Ltd. (HealthCo), with Truong Bao Land International Investment Company Limited (TBL) responsible for importation, sales, marketing, and distribution in Vietnam. TBL will also utilize the local medical distribution networks in Vietnam of associated company Nam Thanh Trade and Medical Services Company Limited 3. The initial supply contract for the first shipments of VIRALEZETM has a maximum three-month term and will be replaced by an ongoing distribution arrangement, which is currently being finalized. These arrangements are exclusive for retail, pharmacies, clinics, and hospitals in Vietnam. The first shipment of VIRALEZETM is expected in Vietnam in early November 2021 and launch preparations for the product are already well advanced with promotions to start shortly. A portion of VIRALEZETM from these orders will be donated to hospitals and other healthcare organizations in Vietnam. Under the initial contract, Starpharma will supply VIRALEZETM, with TBL responsible for sales, distribution, and marketing of the product locally in Vietnam. Registration of VIRALEZETM in Vietnam is already well advanced with full registration expected in the coming weeks following the final listing step. VIRALEZETM is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZETM, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZETM is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane -that traps and irreversibly inactivates virus. VIRALEZETM is registered in Europe and India, and available online in certain markets. VIRALEZETM is partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, and Starpharma is in advanced discussions with potential commercial partners elsewhere in Europe, Asia, India, and other regions. VIRALEZETM is not registered for sale or supply in Australia.
© S&P Capital IQ 2022
Copier lien
All news about STARPHARMA HOLDINGS LIMITED
1d ago
2d ago
12/15
12/14
12/13